Ethical Dimensions of Pharmaceutical Advertising in Nigeria: Media Practices, Regulatory Oversight, and Implications for Public Health Policy

Introduction: Pharmaceutical advertising plays a critical role in shaping medicine use, prescribing behaviour, and public perceptions of health. While ethical promotion can support informed decision-making and rational medicine use, inappropriate or misleading advertising poses significant risks to patient safety and public health, particularly in low- and middle-income countries (LMICs). This narrative review examines the ethical dimensions, media practices, and regulatory oversight of pharmaceutical advertising in Nigeria, with a focus on implications for public health and policy.
Methods: A comprehensive review of peer-reviewed literature, regulatory instruments, policy documents, and grey literature were conducted to synthesise evidence on ethical standards governing pharmaceutical promotion, dominant advertising strategies across traditional and digital media, and the effectiveness of existing regulatory frameworks. International ethical benchmarks, including World Health Organization and International Pharmaceutical Federation guidance, were used to assess Nigerian practices within a global context.
Key Findings/Discussion: The review finds persistent ethical challenges in pharmaceutical advertising in Nigeria, including exaggerated therapeutic claims, inadequate risk disclosure, exploitation of consumer vulnerability, and increasing use of digital and influencer-driven marketing with limited regulatory oversight. Although Nigeria has a multi-agency regulatory architecture involving NAFDAC, the Advertising Regulatory Council of Nigeria, and the Pharmacy Council of Nigeria, institutional overlaps, enforcement gaps, and limited capacity, particularly in digital media monitoring undermine effective governance. These challenges contribute to irrational medicine use, self-medication, antimicrobial misuse, and erosion of public trust.
Conclusion: The review highlights the need for stronger inter-agency coordination, clearer regulatory mandates, enhanced digital surveillance mechanisms, professional training, and public media literacy.
Strengthening ethical pharmaceutical advertising is essential to safeguarding public health, promoting rational medicine use, and advancing medicines governance in Nigeria and comparable LMIC settings.

Pharmaceutical advertising, Drug

1. Adibe, M. O., Igboeli, N. U., Ubaka, C. M., Udeogaranya, P. O., Onwudiwe, N. P., & Ita, O. O. (2015).Evaluation of information contained in drug advertisement and promotion materials in Nigeria. Tropical Journal of Pharmaceutical Research, 14(3), 539–544.https://doi.org/10.4314/tjpr.v14i3.25 [Google Scholar] [Crossref]

2. Ahaiwe, E. O. (2019).Advertising media regulation and sale of herbal medicines in Nigeria: Implication for public health and safety. RSU Journal of Strategic and Internet Business, 4(2), 612–631. [Google Scholar] [Crossref]

3. Ajilore, K., Ojo, O. T., & Onyenankeya, K. (2019).Perception of direct-to-consumer pharmaceutical drug advertising in Nigeria. Malaysian Journal of Consumer and Family Economics, 23, 100–122. [Google Scholar] [Crossref]

4. Auta, A., Shalkur, D., Omale, S., & Abiodun, A. H. (2018).Medicine vendors and self-medication practices in Nigeria. Journal of Pharmaceutical Policy and Practice, 11, 14.https://doi.org/10.1186/s40545-018-0145-1 [Google Scholar] [Crossref]

5. Bélisle-Pipon, J.-C. (2022).Pharmaceutical marketing ethics: Ethical standards for more acceptable practices. Journal of Global Marketing, 35(1), 76–98. https://doi.org/10.1080/08911762.2021.1939469 [Google Scholar] [Crossref]

6. Boltena, M. T., Wolde, M., Hailu, B., El-Khatib, Z., & Steck, V. (2024).Point prevalence of evidencebased antimicrobial use among hospitalized patients in sub-Saharan Africa: A systematic review and meta-analysis. Scientific Reports, 14, 62651. https://doi.org/10.1038/s41598-024-62651-6 [Google Scholar] [Crossref]

7. Braun, V., & Clarke, V. (2006).Using thematic analysis in psychology. Qualitative Research in Psychology, 3(2), 77–101.https://doi.org/10.1191/1478088706qp063oa [Google Scholar] [Crossref]

8. Chikordi, O. E. (2024).What is pharmaceutical marketing? Concepts, scope, and ethical considerations. Journal of Pharmaceutical Policy and Practice, 17, 118. https://doi.org/10.1186/s40545-024-00618-3 [Google Scholar] [Crossref]

9. Chimukuche, R. S., et al. (2024).Lessons from drug promotion during COVID-19 in Africa: A scoping review. Global Health Action. https://doi.org/10.1080/17441692.2024.2323028 [Google Scholar] [Crossref]

10. DeFrank, J. T., Berkman, N. D., Kahwati, L., Cullen, K., Aikin, K. J., & Sullivan, H. W. (2020).Directto-consumer advertising of prescription drugs and the patient–prescriber encounter: A systematic review. Health Communication, 35(6), 739–746. https://doi.org/10.1080/10410236.2019.1586281 [Google Scholar] [Crossref]

11. Erhun, W. O., & Erhun, M. O. (2003).The qualitative impact of broadcast media advertisement on the perception of medicines in Nigeria. Journal of Consumer Behaviour, 3(1), 8–19.https://doi.org/10.1002/cb.119 [Google Scholar] [Crossref]

12. Fadare, J. O., Oshikoya, K. A., Ogunleye, O. O., Desalu, O. O., Ferrario, A., Enwere, O. O., & Godman, B. (2018).Drug promotional activities in Nigeria: Impact on prescribing patterns and practices. Hospital Practice, 46(2), 77–87. https://doi.org/10.1080/21548331.2018.1437319 [Google Scholar] [Crossref]

13. Federal Republic of Nigeria. (2004).National Agency for Food and Drug Administration and Control Act (Cap N1 LFN 2004). Federal Government Press. [Google Scholar] [Crossref]

14. Federal Republic of Nigeria. (2022a).Advertising Regulatory Council of Nigeria Act, 2022 (No. 23). Federal Government Press. [Google Scholar] [Crossref]

15. Federal Republic of Nigeria. (2022b).Pharmacy Council of Nigeria (Establishment) Act, 2022 (No. 31). Federal Government Press. [Google Scholar] [Crossref]

16. Fugh-Berman, A., & Ahari, S. (2021).Following the script: How drug representatives influence physicians. PLOS Medicine, 18(6), e1003621. https://doi.org/10.1371/journal.pmed.1003621 [Google Scholar] [Crossref]

17. Fulone, I., Cadogan, C., Barberato-Filho, S., Bergamaschi, C. C., Mazzei, L. G., Lopes, L. P., & Silva, M. T. (2023).Effects of policies regulating drug marketing. Cochrane Database of Systematic Reviews, 2023(6), CD013780. https://doi.org/10.1002/14651858.CD013780.pub2 [Google Scholar] [Crossref]

18. Greenhalgh, T., Thorne, S., & Malterud, K. (2018).Time to challenge the hierarchy of systematic over narrative reviews? European Journal of Clinical Investigation, 48(6), e12931.https://doi.org/10.1111/eci.12931 [Google Scholar] [Crossref]

19. International Federation of Pharmaceutical Manufacturers and Associations. (2019). IFPMA code of practice. https://www.ifpma.orgInternational Pharmaceutical Federation. (2020).Ethics in pharmaceutical practice. https://www.fip.org [Google Scholar] [Crossref]

20. International Pharmaceutical Federation. (2023).Medicines information: Standards and policy guidance. https://www.fip.org [Google Scholar] [Crossref]

21. Klantschnig, G., & Huang, Y. (2018).Fake drugs: Health, wealth and regulation in Nigeria. Routledge Press. [Google Scholar] [Crossref]

22. Lupton, D. (2022).Data practices, platform power, and health communication. Social Science & Medicine, 292, 114560.https://doi.org/10.1016/j.socscimed.2021.114560 [Google Scholar] [Crossref]

23. McCambridge, J., Mialon, M., & Hawkins, B. (2018).Alcohol industry involvement in policy making: A systematic review. Addiction, 113(9), 1571–1584.https://doi.org/10.1111/add.14216 [Google Scholar] [Crossref]

24. Mintzes, B. (2006).Direct-to-consumer advertising and patient safety. Health Affairs, 25(2), 450– 462.https://doi.org/10.1377/hlthaff.25.2.450 [Google Scholar] [Crossref]

25. Mintzes, B., Herxheimer, A., & Lexchin, J. (2020). [Google Scholar] [Crossref]

26. Direct-to-consumer advertising of prescription medicines. PLOS Medicine, 17(3), e1002995.https://doi.org/10.1371/journal.pmed.1002995 [Google Scholar] [Crossref]

27. Mintzes, B., Lexchin, J., Sutherland, J. M., & Morgan, S. G. (2020). [Google Scholar] [Crossref]

28. Pharmaceutical promotion and public health. BMJ Global Health, 5, e002687. https://doi.org/10.1136/bmjgh-2020-002687 [Google Scholar] [Crossref]

29. Momodu, R. O., Odigie, R., & Udezi, W. A. (2018).Drug Labelling Information and Advertisements in Lagos, Nigeria. Nigerian Journal of Pharmaceutical and Applied Science Research, 7(2), 80–88. [Google Scholar] [Crossref]

30. Mühlhoff, R., & Willem, T. (2023).Social media advertising for clinical studies. Big Data & Society, 10(1).https://doi.org/10.1177/20539517231156127 [Google Scholar] [Crossref]

31. Müller, R., & Fugh-Berman, A. (2021).Marketing of medicines in the digital age. BMJ Global Health, 6(9), e006730.https://doi.org/10.1136/bmjgh-2021-006730 [Google Scholar] [Crossref]

32. Norris, P., Herxheimer, A., Lexchin, J., & Mansfield, P. (2004). Drug promotion: What we know, what we have yet to learn. WHO/HAI. [Google Scholar] [Crossref]

33. OECD. (2020).Consumer policy and fraud in online advertising. OECD Publishing. [Google Scholar] [Crossref]

34. OECD. (2022).Online advertising and consumer protection. OECD Publishing. [Google Scholar] [Crossref]

35. Ogundele, S. O., & Fadare, J. O. (2020).Regulation of medicine promotion in Nigeria. Nigerian Journal of Clinical Practice, 23(9), 1247–1253.https://doi.org/10.4103/njcp.njcp_92_20 [Google Scholar] [Crossref]

36. Oshikoya, K. A., Senbanjo, I. Q., & Soipe, A. (2009). [Google Scholar] [Crossref]

37. Adequacy of pharmacological information in pharmaceutical advertisements. Pharmacy Practice, 7(2), 100–107.https://doi.org/10.4321/S1886-36552009000200002 [Google Scholar] [Crossref]

38. Ozieranski, P., Parnham, J. C., & Mulinari, S. (2021).Pharmaceutical promotion regulation. BMJ, 372, n105.https://doi.org/10.1136/bmj.n105 [Google Scholar] [Crossref]

39. Page, M. J., McKenzie, J. E., Bossuyt, P. M., et al. (2021).PRISMA 2020 statement. BMJ, 372, n71.https://doi.org/10.1136/bmj.n71 [Google Scholar] [Crossref]

40. Qureshi, Z., et al. (2022).Digital marketing of medicines. BMJ Global Health, 7(5), e008123.https://doi.org/10.1136/bmjgh-2021-008123 [Google Scholar] [Crossref]

41. Rodwin, M. A. (2012).Institutional corruption and pharma. Journal of Law, Medicine & Ethics, 40(3), 511–524.https://doi.org/10.1111/j.1748-720X.2012.00675.x [Google Scholar] [Crossref]

42. Rodwin, M. A. (2018).Conflicts of interest and reform. Journal of Law, Medicine & Ethics, 46(2), 350– 366.https://doi.org/10.1177/1073110518782948 [Google Scholar] [Crossref]

43. Sackett, D. L., Rosenberg, W. M., Gray, J. A., Haynes, R. B., & Richardson, W. S. (1996).Evidencebased medicine. BMJ, 312(7023), 71–72.https://doi.org/10.1136/bmj.312.7023.71 [Google Scholar] [Crossref]

44. Siddiq, A., Khan, A., Ali, N., & Ali, Z. (2021).Unethical marketing practices. Webology, 18(6), 7089– 7105. [Google Scholar] [Crossref]

45. Smith, N. C. (2012).Foundations of marketing ethics. Journal of Public Policy & Marketing, 31(1), 1–4.https://doi.org/10.1509/jppm.11.098 [Google Scholar] [Crossref]

46. Spurling, G. K. P., Mansfield, P. R., Montgomery, B. D., et al. (2010). [Google Scholar] [Crossref]

47. Pharmaceutical promotion and prescribing quality. PLOS Medicine, 7(10), e1000352. https://doi.org/10.1371/journal.pmed.1000352 [Google Scholar] [Crossref]

48. Syed Soffian, S. N., Ibrahim, M. I., & Hassali, M. A. (2021). [Google Scholar] [Crossref]

49. Promotion ethics and regulation. International Journal of Clinical Pharmacy, 43(2), 345– 353.https://doi.org/10.1007/s11096-020-01167-5 [Google Scholar] [Crossref]

50. Tricco, A. C., Lillie, E., Zarin, W., et al. (2018).PRISMA-ScR. Annals of Internal Medicine, 169(7), 467–473.https://doi.org/10.7326/M18-0850 [Google Scholar] [Crossref]

51. Uduji, J. I. (2012).Ethical responsibilities in pharmaceutical marketing in Nigeria. International Journal of Business Ethics, 23(1), 1–9. [Google Scholar] [Crossref]

52. Ventola, C. L. (2011).Direct-to-consumer pharmaceutical advertising. P&T, 36(10), 669–684. [Google Scholar] [Crossref]

53. Ventola, C. L. (2014).Social media and healthcare professionals. P&T, 39(7), 491–520. [Google Scholar] [Crossref]

54. Ventola, C. L. (2021).Mobile devices and apps in healthcare. P&T, 46(3), 157–169. [Google Scholar] [Crossref]

55. Vivek, R., Sharma, V., & Singh, A. (2022).Ethics in pharmaceutical marketing. Cureus, 14(9), e29511.https://doi.org/10.7759/cureus.29511 [Google Scholar] [Crossref]

56. World Health Organization. (1988).Ethical criteria for medicinal drug promotion. https://apps.who.int/iris/handle/10665/38125 [Google Scholar] [Crossref]

57. World Health Organization. (2017).Promoting rational use of medicines. https://apps.who.int/iris [Google Scholar] [Crossref]

58. World Health Organization. (2021).Global patient safety action plan 2021–2030. https://www.who.int [Google Scholar] [Crossref]

59. World Health Organization. (2022).Guideline on self-care interventions. https://www.who.int [Google Scholar] [Crossref]

60. World Health Organization. (2023).Global report on effective access to medicines. https://www.who.int [Google Scholar] [Crossref]

61. Yenet A,Nibret G,Tegegne BA(2023):Challenges to the Availabilityand Affordability-of Essential Medicines in African Countries.A Scoping Review.Clinicoecon Outcomes Res.2023,Jun13;15:443458.Doi10,2147/CEOR.S413546.PMID:PMC10276598 [Google Scholar] [Crossref]

62. Yousefi, N., Sharif, Z., Chahian, F., Mombeini, T., & Peiravian, F. (2022). Pharmaceutical advertising in medical journals. Journal of Pharmaceutical Policy and Practice, 15(1), 1–10.https://doi.org/10.1186/s40545-022-00415-1 [Google Scholar] [Crossref]

63. Yusuff, K. B., & Yusuf, A. A. (2009).Advertising of OTC products in a Nigerian urban setting. Nigerian Quarterly Journal of Hospital Medicine, 19(3), 123–129. [Google Scholar] [Crossref]

• Tribal Child Nutrition and Health in District of Sundargarh: A Public Health Review of ICDS Intervention
• Knowledge, Attitudes and Practices Towards Prostate Cancer Screening Amongst Men Aged 40-60 Years in The Buea Health District: A Cross-Sectional Study
• Compliance with JCI Protocols: A Focus on Employee Safety
• Influence and Involvement of Teachers in Menstrual Hygiene Management of Female Secondary School Students in Kogi State, Nigeria
• A Critical Evaluation of Ayushman Bharat Pradhan Mantri Jan Arogya Yojana in Bihar